Analyzing The Cellular and Genetic Alterations That Contribute to The Metastatic Spread of Malignant Tumors
DOI:
https://doi.org/10.63682/jns.v14i32S.9203Keywords:
metastasis, mutations, EMT, prognosisAbstract
Background: The number one cause of cancer-related deaths across the globe is metastatic spread of malignant tumors. To determine therapeutic targets, it is important to understand cellular and genetic changes that facilitate invasion, dissemination, and colonization. Although this field can be improved through genomics, the interactions between tumor-intrinsic alterations and the microenvironment are not fully outlined, and thus, current metastasis-preventive approaches are limited.
Objective: The purpose of the study was to examine cellular changes and genetic mutations related to tumor metastasis, to examine individual patient features, and to examine clinical correlations that point to possible areas of therapeutic intervention.
Study Design: A retrospective observational study.
Place and Duration of study: Pakistan Institute of Medical Sciences, PIMS, Islamabad, Pakistan. Jan 2024 to December 2024
Methods: Review of 100 patients with histologically proven malignant tumors was a retrospective observational study. Institutional records were used to collect demographic and clinical data. Recurrent mutations in TP53, KRAS, and PIK3CA of tumor tissue samples and epithelial-mesenchymal transition markers were assessed by immunohistochemistry. Statistical analyses comprised descriptive statistics, calculation of mean ages and standard deviation and comparison of groups using Student t-test with a significance level set to p < 0.05.
Results: 100 patients (52 males and 48 females) were used as the cohort. The mean age was 59.4 years +- 11.2 SD. Genomic findings identified TP53 mutations in 45 percent of patients, KRAS mutations in 28 percent and PIK3CA mutations in 18 percent. Loss of E-cadherin expression was also found in 36 percent of samples and was associated with greater invasiveness. Analysis of the metastatic burden revealed that patients who had both TP53 and KRAS mutations had a much greater metastatic burden than patients without (p = 0.018). Clinical associations suggested that genetic changes and epithelial-mesenchymal transition signatures operated as a combined effect on progression, which underscored a suggestion that molecular heterogeneity is the basis of metastatic potential.
Conclusion: We have shown that genetic mutations, together with cellular reprogramming (epithelial-mesenchymal transition) contribute to metastasis. Combined TP53 and KRAS mutations and their relationship with metastatic progression are correlated, which is important to identify potential risk stratification biomarkers. The combination of molecular and cellular analysis provides informative tools to develop therapies that will help intercept metastatic progression, which ultimately will raise the prognosis and survival rates in patients with progressive malignant tumors.
Downloads
Metrics
References
Etzerodt A, Moulin M, Doktor TK, Delfini M, Mossadegh-Keller N, Bajenoff M. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. The Journal of experimental medicine. 2020;217(4).
Sbaraglia M, Gambarotti M, Businello G, Righi A, Fassan M, Dei Tos AP. Intra-Articular Tumors. Surgical pathology clinics. 2021;14(4):665-77.
Michalski BM, Pfeifer JD, Mutch D, Council ML. Cancer of the Vulva: A Review. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2021;47(2):174-83.
Russo A, Gangi A. The Evolving Landscape of Neuroendocrine Tumors. Surgical oncology clinics of North America. 2023;32(1):185-98.
Hu Z, Li Z, Ma Z, Curtis C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nature genetics. 2020;52(7):701-8.
Shimon I. Metastatic Spread to the Pituitary. Neuroendocrinology. 2020;110(9-10):805-8.
Banerjee K, Kerzel T, Bekkhus T, de Souza Ferreira S, Wallmann T, Wallerius M. VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. Cell reports. 2023;42(12):113507.
Trerotola M, Guerra E, Ali Z, Aloisi AL, Ceci M, Simeone P. Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis. Neoplasia (New York, NY). 2021;23(4):415-28.
Lord AC, Knijn N, Brown G, Nagtegaal ID. Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease. European journal of cancer (Oxford, England : 1990). 2020;128:1-6.
Walocko F, Christensen RE, Worley B, Alam M. Cutaneous Mesenchymal Sarcomas. Dermatologic clinics. 2023;41(1):133-40.
Hill BS, Sarnella A, D'Avino G, Zannetti A. Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Seminars in cancer biology. 2020;60:202-13.
Aly R, Emmady PD. Paraneoplastic Cerebellar Degeneration. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Prabhu Emmady declares no relevant financial relationships with ineligible companies.: StatPearls Publishing. Copyright © 2025, StatPearls Publishing LLC.; 2025.
Shirahata M, Mishima K. [Metastatic Brain Tumors]. Brain and nerve = Shinkei kenkyu no shinpo. 2021;73(1):5-11.
Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang H, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184(9):2471-86.e20.
Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer letters. 2022;530:156-69.
Yin Y, Dai H, Sun X, Xi Z, Zhang J, Pan Y. HRG inhibits liver cancer lung metastasis by suppressing neutrophil extracellular trap formation. Clinical and translational medicine. 2023;13(6):e1283.
Guo J, Savic LJ, Hillebrandt KH, Sack I. MR Elastography in Cancer. Investigative radiology. 2023;58(8):578-86.
Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocrine pathology. 2022;33(1):90-114.
Satcher RL, Zhang XH. Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nature reviews Cancer. 2022;22(2):85-101.
Kopcik K, Kościelecka K, Krzyżak K. Cardiac Metastatic Tumors: Current Knowledge. American journal of clinical oncology. 2023;46(8):374-9.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
